Trinity Biotech AI Stock Analysis
Want to see TRIB full AI Analyst Report?
Trinity Biotech (TRIB) AI Stock Analysis
Trinity Biotech
(NASDAQ:TRIB)
The score is weighed down primarily by weak financial performance (sustained losses, negative equity, rising debt, and ongoing cash burn). Technical indicators also point to a strong downtrend with bearish momentum, only partially offset by oversold conditions. Valuation offers limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Trinity Biotech (TRIB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $117.86M
- Dividend Yield
- ―
- Average Volume (3M)
- 17.58K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 2.86
- Revenue Growth
- -13.28%
- EPS Growth
- 39.65%
- Country
- US
- Employees
- 287
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Specialties
Trinity Biotech Business Overview & Revenue Model
Company Description
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Afric...
How the Company Makes Money
Trinity Biotech primarily makes money by selling diagnostic products and related consumables used to run clinical tests. Key revenue streams have historically included: (1) Reagents and test kits: recurring sales of assay reagents and test kits (for...
Trinity Biotech Earnings Call Summary
The earnings call reflected a company in transition, with significant improvements in revenue growth and cost reduction measures. However, challenges remain, particularly in the hemoglobin segment and overall net loss, indicating a mixed outlook.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During Trinity Biotech's Q3 2024 earnings call, the company reiterated its guidance for 2024, projecting TrinScreen HIV sales revenue of approximately $10 million and annualized run rate revenues of around $75 million by Q2 2025. The company reported a 3% year-on-year revenue growth, reaching $15.2 million for Q3 2024, primarily driven by a 60% increase in point-of-care revenues due to TrinScreen sales. Operating loss improved by 51% to $2.2 million before restructuring and impairment charges. The company aims to achieve approximately $20 million of annualized run rate EBITDASO by Q2 2025 through comprehensive transformation initiatives, including cost reductions and operational efficiencies.
Trinity Biotech Financial Statement Overview
Summary
Financial quality is very weak: multi-year large losses, persistently negative shareholder equity, sharply rising debt, and negative operating/free cash flow (despite some 2025 free cash flow improvement). Solvency and liquidity risk remain elevated until profitability and cash generation materially recover.
Income Statement
18Very NegativeBalance Sheet
9Very NegativeCash Flow
22Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 43.86M | 43.78M | 61.55M | 56.83M | 62.52M | 81.15M |
| Gross Profit | 15.53M | 16.89M | 21.44M | 19.45M | 22.05M | 33.45M |
| EBITDA | -8.57M | -21.38M | -16.91M | -24.10M | -16.71M | 10.59M |
| Net Income | -37.43M | -37.38M | -31.79M | -24.02M | -41.00M | 875.00K |
Balance Sheet | ||||||
| Total Assets | 105.17M | 105.17M | 103.29M | 59.44M | 92.10M | 118.89M |
| Cash, Cash Equivalents and Short-Term Investments | 5.14M | 5.14M | 5.17M | 3.69M | 6.58M | 25.91M |
| Total Debt | 137.98M | 137.98M | 100.76M | 67.43M | 72.20M | 99.16M |
| Total Liabilities | 177.15M | 177.15M | 138.47M | 83.38M | 94.28M | 119.21M |
| Stockholders Equity | -71.98M | -71.98M | -35.18M | -23.95M | -2.18M | -319.00K |
Cash Flow | ||||||
| Free Cash Flow | -6.34M | -12.15M | -14.26M | -12.36M | -6.90M | 4.55M |
| Operating Cash Flow | -6.26M | -5.93M | -4.19M | -11.56M | -921.00K | 13.24M |
| Investing Cash Flow | -6.24M | -6.22M | -22.97M | 24.76M | -5.98M | -8.69M |
| Financing Cash Flow | 12.40M | 12.05M | 28.81M | -16.04M | -12.32M | -6.02M |
Trinity Biotech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRIB, the sentiment is Negative. The current price of 5.82 is below the 20-day moving average (MA) of 6.84, below the 50-day MA of 7.08, and below the 200-day MA of 14.71, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 39.60 is Neutral, neither overbought nor oversold. The STOCH value of 34.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRIB.
Trinity Biotech Risk Analysis
Trinity Biotech disclosed 1 risk factors in its most recent earnings report. Trinity Biotech reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksTrinity Biotech Peers Comparison
Overall Rating
PRPO56Neutral
BNGO51Neutral
INBS46Neutral- TRIB42Neutral
BIAF40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PRPO | 56Neutral | $42.34M | -41.02 | -7.84% | ― | 21.76% | 22.97% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BNGO | 51Neutral | $17.19M | -0.41 | -85.00% | ― | 8.23% | 82.76% |
| INBS | 46Neutral | $7.46M | -0.31 | -146.09% | ― | 36.55% | 60.09% |
| TRIB | 42Neutral | $3.79M | -0.13 | 48.72% | ― | -13.28% | 39.65% |
| BIAF | 40Underperform | $4.35M | -0.04 | -331.02% | ― | -18.47% | 87.82% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TRIB | Trinity Biotech | 5.82 | -19.76 | -77.25% | |
| PRPO | Precipio | 24.80 | 5.28 | 27.05% | |
| BNGO | Bionano Genomics | 1.10 | -0.37 | -25.17% | |
| INBS | Intelligent Bio Solutions Inc. | 2.10 | -5.06 | -70.67% | |
| BIAF | bioAffinity Technologies, Inc. | 2.42 | -25.77 | -91.40% |
Trinity Biotech Corporate Events
Trinity Biotech Shareholders Back All Resolutions at September 30 AGM
Trinity Biotech reported that at its annual general meeting held on September 30, 2026, shareholders approved all resolutions with at least 95% of votes cast, underscoring strong investor support for the company’s governance and oversight framework....
Trinity Biotech’s Trinovium Unit Signs AI Data Center Cooling Pilot Deal with Red Team Investments
On September 9, 2026, Trinity Biotech’s Trinovium subsidiary signed a contract with Texas-based Red Team Investments to supply advanced fluids and analytical systems for a U.S. commercial pilot of direct-to-chip liquid cooling in AI and high-performa...
Trinity Biotech Files 2025 Annual Report and AGM Materials with SEC
On September 8, 2026, Trinity Biotech filed a Form 6-K with the U.S. Securities and Exchange Commission, furnishing its Annual Report for 2025 to investors. The filing confirms compliance with U.S. reporting requirements and incorporates the report i...
Trinity Biotech Advances Diagnostics Transformation as Nasdaq Compliance Pressure Mounts
On August 28, 2026, Trinity Biotech reported progress in its diagnostics business, highlighting the appointment of Jordi Romero as Head of Commercial Operations – Europe to strengthen sales execution and accelerate growth in key international markets...
Trinity Biotech’s Trinovium Strikes Liquid Cooling Collaboration with Echelon for AI Data Centers
On August 17, 2026, Trinity Biotech’s Trinovium subsidiary entered into a strategic collaboration with Echelon Data Centres to develop advanced liquid cooling solutions for AI and high-density computing infrastructure. The partnership combines Trinov...
Trinity Biotech Gains $7 Million from Perceptive Advisors and Restores Nasdaq Bid Price Compliance
On August 14, 2026, Trinity Biotech announced it had secured approximately $7.0 million in additional investment from funds managed by Perceptive Advisors, its largest financial investor and primary lender, via an amendment to its term loan facility...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 15, 2026